<sup>18</sup>F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer-Reference-Cited by-同舟云学术

¹⁸F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer

Published:2024-03-21 Issue:5 Volume:65 Page:722-727
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Cytryn Samuel L.,Pandit-Taskar Neeta,Lumish Melissa A.,Maron Steven B.,Gu Ping,Ku Geoffrey Y.,Chou Joanne F.,Capanu Marinela,Antoine Ariel,Loegel Diane,Feder Lara,Philemond Steven,Lyashchenko Serge K.,Lewis Jason S.,Paroder Viktoriya,Srivastava Amitabh,Tang Laura H.,Schoder Heiko,Janjigian Yelena Y.

Publisher

Society of Nuclear Medicine

Reference17 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

3. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

4. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial;Janjigian;Lancet.,2023

5. High interobserver variability among pathologists using combined positive score to evaluate PD-L1 expression in gastric, gastroesophageal junction, and esophageal adenocarcinoma;Robert;Mod Pathol.,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptide-based immuno-PET/CT monitoring of dynamic PD-L1 expression during glioblastoma radiotherapy;Journal of Pharmaceutical Analysis;2024-08